Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylphenidate (OROS formulation).

G M Keating1, K McClellan, B Jarvis

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|August 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proton damage in (Y,Lu,Gd)<sub>3</sub>(Al,Ga)<sub>5</sub>O<sub>12</sub>:Ce mixed garnet scintillators.

The Review of scientific instruments·2022
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2015
Same author

Application of Illumina next-generation sequencing to characterize the bacterial community of the Upper Mississippi River.

Journal of applied microbiology·2013
Same author

Stachybotrys: An unusual mold associated with water-damaged buildings.

Mycotoxin research·2013
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2010
Same author

Brain sex differences and hormone influences: a moving experience?

Journal of neuroendocrinology·2009
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

This study shows that the OROS methylphenidate formulation effectively treats attention deficit/hyperactivity disorder (ADHD) in children. Once-daily OROS methylphenidate demonstrated sustained efficacy and a similar tolerability profile to immediate-release methylphenidate.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatrics

Background:

  • Methylphenidate is a central nervous system stimulant.
  • It is believed to inhibit dopamine and noradrenaline reuptake.
  • The OROS formulation offers sustained release for attention deficit/hyperactivity disorder (ADHD).

Purpose of the Study:

  • To evaluate the efficacy and tolerability of OROS methylphenidate in children with ADHD.
  • To compare the pharmacokinetic profile of OROS methylphenidate in children and adults.
  • To assess the long-term efficacy of OROS methylphenidate.

Main Methods:

  • A clinical trial involving 282 children with ADHD.
  • Administration of once-daily OROS methylphenidate (18-54 mg) or placebo.
  • Comparison with immediate-release (IR) methylphenidate (5-15 mg 3 times daily).

Related Experiment Videos

  • A 1-year noncomparative study for sustained efficacy assessment.

    • Main Results:

    • Once-daily OROS methylphenidate was significantly more effective than placebo in reducing ADHD symptoms.
    • OROS methylphenidate showed efficacy comparable to IR methylphenidate.
    • The OROS formulation exhibited sustained efficacy over 1 year.
    • Pharmacokinetic profiles differed between OROS methylphenidate and other formulations in adults.

    Conclusions:

    • OROS methylphenidate is an effective and well-tolerated treatment for pediatric ADHD.
    • The sustained-release formulation provides a convenient once-daily dosing option.
    • OROS methylphenidate demonstrates comparable efficacy and tolerability to immediate-release methylphenidate.